Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis

Abstract

Response-adapted therapy using interim functional imaging (IFI) was retrospectively examined in a cohort of 124 patients with advanced classical Hodgkin lymphoma receiving 2 front-line regimens (ABVD [doxorubicin, bleomycin, vinblastine, and dacarbazine] and eBEACOPP [escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone]). We observed that IFI is an independent predictor of progression-free survival in advanced classical Hodgkin lymphoma and can guide therapeutic decisions in the real world. Given the inferior outcome seen in patients with a positive IFI, novel approaches of therapy are warranted.